OBJECTIVE: To explore the role of clinical pathway of drug therapy on management of prophylactic use of proton pump inhibitors（PPI） during perioperative period in head and neck surgery. METHODS: Patients discharged from the department of head and neck surgery of the hospital from Apr. to Sept. 2021 were selected as the pre-management group

and patients discharged from the department of head and neck surgery of the hospital from Oct. 2021 to Mar. 2022 were selected as the post-management group. Clinical pathway management of drug therapy was used to solve the problems in perioperative prophylactic use of PPI in the department of head and neck surgery. Pharmacists and clinicians jointly formulated the clinical pathway of drug therapy for perioperative prophylactic use of PPI. By investigating the indications and treatment courses of PPI before and after clinical pathway of drug therapy management in patients with head and neck surgery

the use of PPI was compared and analyzed. RESULTS: After management

the rational rate of perioperative prophylactic use of PPI in the department of head and neck surgery increased from 72.90%（191/262） to 82.03%（105/128）

and the use rate of PPI decreased from 30.57%（262/857） to 12.04%（128/1 063）

the use intensity of PPI decreased from 24.59 DDDs/（100 persons·d） to 10.49 DDDs/（100 persons·d）

the differences were statistically significant（P<0.05）. CONCLUSIONS: The pathway management model can promote the rational use of PPI in the head and neck surgery during perioperative period

and provide reference for clinical rational drug use.